SCD 101

Drug Profile

SCD 101

Alternative Names: SCD101

Latest Information Update: 21 Jan 2017

Price : $50

At a glance

  • Originator Invenux LLC
  • Developer Invenux LLC; State University of New York
  • Class Antianaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 03 Dec 2016 Adverse events data from a phase Ia trial in Sickle cell anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2016 Invenux plans a phase II trial in Sickle cell anaemia
  • 03 Dec 2016 Invenux plans a clinical trial in Sickle cell anaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top